Biocompatibility of a 1.1% amino acid-containing peritoneal dialysis fluid compared to a 2.27% glucose-based peritoneal dialysis fluid

Nephron

Volumn 74, Issue 1, 1996, Pages 26-32

  Brulez, H F H ^a   Dekker, H A T ^b   Oe, P L ^a   Verbeelen, D ^d   Ter Wee, P M ^a   Verbrugh, H A ^c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d FREE UNIVERSITY OF BRUSSELS   (Belgium)

Author keywords

Amino acids; Biocompatibility; Interleukin 8; Interleukin 1 beta; ; Macrophages; Opsonic activity; Peritoneal; Peritoneal dialysis; Phagocytosis

Indexed keywords

AMINO ACID; GLUCOSE; INTERLEUKIN 1BETA; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; PERITONEAL DIALYSIS FLUID;

ADULT; AGED; ARTICLE; BIOCOMPATIBILITY; CELL CULTURE; CHEMOLUMINESCENCE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MALE; MONOCYTE; PERITONEAL DIALYSIS; PERITONEUM MACROPHAGE; PHAGOCYTOSIS; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACIDS; ASCITIC FLUID; CHEMILUMINESCENT MEASUREMENTS; DIALYSIS SOLUTIONS; FEMALE; GLUCOSE; GRANULOCYTES; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNE SYSTEM; INTERLEUKIN-1; INTERLEUKIN-8; LIPOPOLYSACCHARIDES; MACROPHAGES; MALE; MATERIALS TESTING; MIDDLE AGED; OPSONIN PROTEINS; OSMOLAR CONCENTRATION; PERITONEAL DIALYSIS; PHAGOCYTOSIS; PROTEINS;

EID: 0029783617     PISSN: 16608151     EISSN: 22353186     Source Type: Journal    
DOI: 10.1159/000189277     Document Type: Article

References (29)

1. Lindholm B. Bergstrom J: Nutritional management of patients undergoing peritoneal dialysis: in Nolph KD (ed): Peritoneal Dialysis, ed 3. Dordrecht. Kluwer Acadamic. 1989. pp 230-260.
2. Acchiardo SR. Moore LW. Latour PA: Malnutrition as the main factor in morbidity and mortality of hemodialysis patients. Kidney Int 1983;24(suppl): 199-203.
3. Keusch GT: Nutrition and Infection: in Schaechter(ed): Mechanisms of Microbial Disease. ed 2. Baltimore, Williams & Wilkins, 1987, pp 815-825.
4. Kratka R, Shuler C, Wolfson M: Nutrition in hemodialysis and peritoneal dialysis patients; in Nissenson (ed): Clinical Dialysis, ed 2. Englewood Cliffs, Prcnticc-Hall. 1990, pp 350-365.
5. Khanna R, Wu G. Rodella H, Oreopoulos DG: Use of amino acid containing solution in CAPD patients. Perit Dial Bull 1984:4(suppl): 121-126.
6. Pederson FB, Dragsholt C. Laicr E. Frifclt JJ. Trostmann AF. Ekelund S. Paaby P: Alternate use of amino acid and glucose solutions in CAPD. Perit Dial Bull 1985;5:215-218.
7. Dombros NV, Digenis GE, Oreopoulos DG: Malnutrition in continuous ambulatory dialysis and use of intraperitoncal amino acids: in Berlyne GM (ed): The Kidney Today. Selected Topics in Renal Science. Contrib Nephrol. Basel, Karger. 1992. vol 100. pp 188-206.
8. Williams P. Marliss E. Anderson GH. Oren A. Khanna R. Petitt J. Brandes L, Rodella H. Mupas L. Dombros N, Oreopoulos DG: Amino acid absorption following intraperitoneal administration in CAPD patients. Peril Dial Bull 1982:2:124-130.
9. Brulez HFH, Heezius ECJM. de Fijter CWJ, Oe PL. Verhoef J. Verbrugh HA: In vitro compatibility of a 1.,1% amino acid containing peritoneal dialysis fluid with phagocyte function. AdvPeritDial 1994:10:241-244.
10. Verbrugh HA. Hoidal JR. Nguyen BYT, Verhoef J. Quie PG. Peterson PK: Human alveolar macrophage cytophilic immunoglobulin G-me-diated phagocytosis of protein A-positive staphylococci. J Clin Invest 1982:69:63-74.
11. Peterson PK, Verhoef J. Schmcling D. Quie PG: Kinetics of phagocytosis and bacterial killing by human polymorphonuclear leucocytes and monocytes. J Infect Dis 1977:136:502-509.
12. Verbrugh HA. Peters R. Peterson PK. Verhoef J: Phagocytosis and killing of staphylococci by human polymorphonuclear and mononuclear leucocytes. J Clin Pathol 1978;31:539-545.
13. Bjerknes R. Bassoe CF. Sjursen H, Laerum OD, Solberg CO: Row cytometry for the study of phagocyte functions. Rev Infect Dis 1989; 11:16-33.
14. Van Strijp JAG. van Kessel KPM. van den Toi ME, Huit AC. Snippc FI. Verhoef J: Phagocytosis of herpes simplex virus by human granulocytes and monocytes. Arch Virol 1989:104: 287-298.
15. Verbrugh HA. Keane WF. Hoidal JR. Freiberg MR, Elliott GR. Peterson PK: Peritoneal macrophages and opsonins: Antibacterial defense in patients undergoing chronic peritoneal dialysis. J Infect Dis 1983:147:1018-1029.
16. Mills EL. Rholl KS. Quie PG: Luminol-ampli-fied chemiluminescence: A sensitive method for detecting the carrier stale in chronic granulomatous disease. J Clin Microbiol 1980; 12: 52-56.
17. Van Bronswijk H. Verbrugh HA. Heezius HCJM. Van der Meulen J, Oc PL. Verhoef J: Dialysis Fluid and local host resistance in patients on continuous ambulatory peritoneal dialysis. Eur J Clin Microbiol Infect Dis 1988:7: 368-373.
18. Timmerman CP, Mattsson E, Martinez-Marti-nez L. de Graaf L. van Strijp JAG, Verbrugh HA. Verhoef J, Fleer A: Induction of release of TNF from human monocytes by staphylococci and staphylococcal peptido glycans. Infect Immun 1993;61:4167-4172.
19. Duwe AK, Vas SI. Weathcrhead JW: Effects of the composition of peritoneal dialysis fluid on chemiluminescence. phagocytosis, and bactericidal activity in vitro. Infect Immun 1981;33: 130-135.
20. Jörrcs A. Jörres D. Gahl GM. Kessel M. Miiller C. Kotigen E, Serke S. Schulz E. Mahiout A: Leukotriene R. And tumor necrosis factor release from leukocytes: Effect of peritoneal dial-ysatc. Nephron 1991;58:276-282.
21. McGregor SJ. Brock JH. Briggs JD. Junor BJR: Bactericidal activity of peritoneal macrophages from continuous ambulatory peritoneal dialysis patients. Nephrol Dial Transplant 1987:2: 104-108.
22. Do Fijter CWH, Verbrugh HA. Peters EDJ. Oe PL. van der Meulen J. Verhoef J. Donker AJM: In vivo exposure to the currently available peritoneal dialysis fluids increases the function of peritoneal macrophages in CAPD. Clin Nephrol 1993;39:75-80.
23. Alobaidi HM. Coles GA. Davies M. Lloyd D: Host defence in continuous ambulatory peritoneal dialysis patients. Nephrol Dial Transplanl 1986;1:16-21.
24. Davies SB. Suassuna J. Ogg CS, Cameron JS: Activation of immunocompetent cells in the peritoneum of patients treated with CAPD. Kidney Int 1989;36:661-668.
25. Bos HJ, Struijk DG. Tuk CW, dc Veld JC, Hcl-merhorst TJM. Hocfsmit ECM. Arisz L. Bcclen RHJ: Peritoneal dialysis induces a sterile inflammatory state and the mesothelial cells in effluent arc related to the bacterial peritonitis incidence. Nephron 1991:59:508-509.
26. Betjes MGH. Tuk CW. Struijk DG. Krcdiet RT. Arisz L. Hocfsmit ECM. Beclen RHJ: lm-muno-efTector characteristics of peritoneal cells during CAPD treatment: A longitudinal study. Kidney int 1993:43:641-648.
27. Young GA. Kendall S, Brownjohn AM: Complement activation during CAPD. Nephrol Dial Transplant 1993;8:1372-1375.
28. Fiercn MWJA. van den Bemd GJCM, Bonta IL: Endotoxin-stimulated peritoneal macrophages obtained from continuous ambulatory peritoneal dialysis patients show an increased capacity to release interleukin-Ip in vitro during infectious peritonitis. Eur J Clin Invest 1990;20:453-457.
29. Takada A. Shirahama S. Takada Y: Inhibition of the activation of the first component of complement, Cl. by various amino acids or peptides. Immunopharmacologv 1984;8:27-35.